Table 6.
Univariate and stepwise multivariate analysis of risk factors for CNS involvement in primary Sjögren’s syndrome
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Odds ratios | 95% CI | p value | Odds ratios | 95% CI | p value | |
| Hematologic changes, n (%) | 2.15 | 1.05–4.40 | 0.037 | - | ||
| Lung involvement, n (%) | 2.20 | 1.06–4.54 | 0.034 | 2.50 | 1.11–5.59 | 0.026 |
| Kidney involvement, n (%) | 4.22 | 1.24–14.4 | 0.021 | - | ||
| ANA positive, n (%) | 8.14 | 1.93–34.3 | 0.004 | - | ||
| Anti‐SSA positive, n (%) | 6.62 | 2.32–18.9 | 0.000 | 3.63 | 1.12–11.8 | 0.032 |
| RF positive, n (%) | 1.49 | 0.78–2.84 | 0.225 | - | ||
| C3 < 0.8 g/L | 4.26 | 2.21–8.20 | 0.000 | 2.30 | 1.03–5.14 | 0.043 |
| C4 < 0.2 g/L | 3.52 | 1.79–6.92 | 0.000 | - | ||
| PLT < 30 × 109/L, n (%) | 1.53 | 0.56–4.19 | 0.406 | - | ||
ANA, antinuclear antibodies; C3, complement component 3; C4, complement component 4; RF, rheumatoid factor; PLT, platelet